Finland's research and development of nasal spray new crown medicament obtained patent

Xinhua News Agency, Helsinki, May 24 (Reporter Chen Jing and Xu Qian) According to a report by the Finnish National Broadcasting Corporation on the 24th, a new nasal spray new crown drug developed by Therapeutica Borealis, a Finnish pharmaceutical company, has obtained a patent authorization from the US Patent and Trademark Office.

According to reports, this nasal spray contains active ingredients such as aprotinin, hydroxychloroquine and ivermectin.

The company said, “The active substances used in the new drugs are well-known and commonly used drugs, but in the present invention, these active substances are used in the upper respiratory tract mucosa in a new targeted way.

In a telephone interview with Xinhua News Agency, the main developer of the new drug, Carlylvo Vernell, said that because the principle of the nasal spray is to target the human body rather than the virus, the mutant virus has little effect on its efficacy.